Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by wiseinvestor2on Feb 08, 2016 11:57am
136 Views
Post# 24535665

Breathtec Biomedical Inc. C.BTH

Breathtec Biomedical Inc. C.BTH

Breathtec Biomedical Inc. (“Breathtec”) aims to propel development and commercialization of breath analysis screening technologies.

  • Breathtec holds an option to acquire key University of Florida patent U.S. 8,237,118 entitled “Partial Ovoidal FAIMS Electrode.”
  • FAIMS is a mass spectrometry technique that exploits differences in ion mobility at very high electric fields, to separate ions in the millisecond timescale after liquid chromatography separation and prior to introduction to a mass spectrometer.

FAIMS technology allows for miniaturization of breath testing devices and will enable development of non-invasive clinical screening.

  • Eventual commercialization of FAIMS could revolutionize early detection of many deadly diseases.
  • The Company is actively pursuing multiple, alternative research efforts into FAIMS technology.

Our Goal:

Develop a handheld breathalyzer

  • Simplifies detection of diseases
  • Real-time breath analysis

Non-invasive & Non-intrusive

  • Collection anywhere, anytime
  • Rapid results (minutes, not hours or days)
  • Minimal handling/storage procedures
  • Relatively simple analysis

Three Key Form Factors

Affordable

  • Miniaturized electronics & sensors
  • disposable consumables

Portable

  • Phase one: desktop
  • Phase two: handheld

Adaptable

  • Internet connected
  • Software updates
  • Remote data capable
Bullboard Posts